Compare SLS & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLS | PK |
|---|---|---|
| Founded | 2012 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2007 | 2014 |
| Metric | SLS | PK |
|---|---|---|
| Price | $11.62 | $15.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $11.22 |
| AVG Volume (30 Days) | ★ 6.9M | 3.7M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 8.82% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $2,791,000,000.00 |
| Revenue This Year | N/A | $2.40 |
| Revenue Next Year | $110.98 | $2.76 |
| P/E Ratio | ★ N/A | $52.69 |
| Revenue Growth | N/A | ★ 2.35 |
| 52 Week Low | $1.39 | $9.84 |
| 52 Week High | $15.88 | $16.20 |
| Indicator | SLS | PK |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 50.26 |
| Support Level | $12.64 | $10.82 |
| Resistance Level | $15.77 | $15.48 |
| Average True Range (ATR) | 1.12 | 0.40 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 29.70 | 27.73 |
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 19,902 rooms across 29 hotels in the United States. Park also has an interest through a joint venture in another 1,424 rooms in another US hotel. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.